Stewart Appelrouth
Known title: DirectorCIK: 0001702626
Stewart Appelrouth's purchase track record
How the stock did after each of Stewart Appelrouth's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since January 3, 2023
Stock higher 6 months later
25%
3 months: 50%
Median 6-month return
-32.0%
3 months: +0.7%
Beat the S&P 500
25%
median -36.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2024 | AIM | $2K | -45.5% | -68.2% | -1.8% |
| 11/20/2024 | AIM | $16K | -35.0% | -55.0% | -1.2% |
| 3/15/2024 | AIM | $30K | +36.4% | -9.1% | +10.0% |
| 1/3/2023 | AIM | $25K | +40.6% | +103.1% | +16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AIM | ▲ Buy | Grant | 8,768 | $2K | 12/31/2024 | View on chart |
| AIM | ▲ Buy | Grant | 24,452 | $5K | 12/13/2024 | View on chart |
| AIM | ▲ Buy | Open Market | 1 | $0 | 12/2/2024 | View on chart |
| AIM | ▲ Buy | Open Market | 11,111 | $2K | 12/2/2024 | View on chart |
| AIM | ▲ Buy | Grant | 22,645 | $5K | 12/2/2024 | View on chart |
| AIM | ▲ Buy | Open Market | 81,953 | $16K | 11/20/2024 | View on chart |
| AIM | ▲ Buy | Open Market | 90,910 | $30K | 3/15/2024 | View on chart |
| AIM | ▼ Sell | Other | 68,208 | $84K | 3/10/2023 | View on chart |
| AIM | ▲ Buy | Open Market | 80,646 | $25K | 1/3/2023 | View on chart |
| AIM | ▲ Buy | Grant | 24,500 | $26K | 4/25/2022 | View on chart |
| AIM | ▲ Buy | Grant | 19,379 | $25K | 11/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress
AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress. AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.